
Mitchell F Brin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3348267/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD. Cephalalgia, 2022, 42, 933-943.	3.9	12
2	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. Cephalalgia, 2022, , 033310242210998.	3.9	3
3	Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia, 2021, 41, 17-32.	3.9	20
4	OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood–brain barrier. Pain, 2021, 162, 2418-2427.	4.2	2
5	The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial. EClinicalMedicine, 2020, 24, 100429.	7.1	44
6	Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA. Toxins, 2020, 12, 661.	3.4	1
7	Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia, 2019, 39, 1358-1365.	3.9	27
8	Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30â€year experience. Laryngoscope, 2018, 128, S1-S9.	2.0	51
9	Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection. Neuroscience, 2017, 352, 155-169.	2.3	49
10	Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?. Cephalalgia, 2016, 36, 875-886.	3.9	101
11	Negative dystonia of the palate: A novel entity and diagnostic consideration in hypernasal speech. Laryngoscope, 2015, 125, 1426-1432.	2.0	4
12	Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics: Targets and Therapy, 2014, 8, 227.	3.2	70
13	Reply. Dermatologic Surgery, 2014, 40, 1419-1420.	0.8	Ο
14	Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. Journal of Drugs in Dermatology, 2011, 10, 39-44.	0.8	28
15	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Doubleâ€Blind, Randomized, Placeboâ€Controlled Phases of the PREEMPT Clinical Program. Headache, 2010, 50, 921-936.	3.9	779
16	Pooled Analysis of the Safety of Botulinum Toxin Type A in the Treatment of Poststroke Spasticity. Archives of Physical Medicine and Rehabilitation, 2006, 87, 786-792.	0.9	76